This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/news/521939-eu-vaccine-deal-pfizer/

The article has changed 3 times. There is an RSS feed of changes available.

Version 0 Version 1
EU to strike world’s largest Covid-19 vaccine deal with Pfizer, as WHO warns poorest countries still struggling for access EU to strike world’s largest Covid-19 vaccine deal with Pfizer, as WHO warns poorest countries still struggling for access
(4 months later)
The European Commission says it has agreed to buy up to 1.8 billion doses of the Pfizer/BioNTech Covid-19 vaccine – the world’s biggest supply deal – amid concerns over unequal access for the world’s poorest nations.The European Commission says it has agreed to buy up to 1.8 billion doses of the Pfizer/BioNTech Covid-19 vaccine – the world’s biggest supply deal – amid concerns over unequal access for the world’s poorest nations.
The additional doses of the vaccine developed by US drug maker Pfizer and Germany’s BioNTech will be delivered from 2021 to 2023, European Commission President Ursula von der Leyen said at a briefing on Friday, adding that they will be used as booster shots.The additional doses of the vaccine developed by US drug maker Pfizer and Germany’s BioNTech will be delivered from 2021 to 2023, European Commission President Ursula von der Leyen said at a briefing on Friday, adding that they will be used as booster shots.
The amount of doses ordered of the two-shot Comirnaty vaccine would be enough to inoculate the EU population of 450 million people twice over. A commission spokesperson told Reuters that half of the vaccines would be optional.The amount of doses ordered of the two-shot Comirnaty vaccine would be enough to inoculate the EU population of 450 million people twice over. A commission spokesperson told Reuters that half of the vaccines would be optional.
This is the third contract between the EU and Pfizer/BioNTech, with supplies of 600 million doses agreed under the two previous contracts.This is the third contract between the EU and Pfizer/BioNTech, with supplies of 600 million doses agreed under the two previous contracts.
“We will conclude in the next days. It will secure the doses necessary to give booster shots to increase immunity,” von der Leyen said during a visit to Pfizer’s vaccine plant in Belgium.“We will conclude in the next days. It will secure the doses necessary to give booster shots to increase immunity,” von der Leyen said during a visit to Pfizer’s vaccine plant in Belgium.
The deal comes as the World Health Organization slammed the inequity in the distribution of Covid-19 vaccines. In a report released on Friday, marking a year since the launch of the international COVAX dose-sharing facility, the head of the WHO said vaccines remain out of reach for the poorest countries.The deal comes as the World Health Organization slammed the inequity in the distribution of Covid-19 vaccines. In a report released on Friday, marking a year since the launch of the international COVAX dose-sharing facility, the head of the WHO said vaccines remain out of reach for the poorest countries.
“Nearly 900 million vaccine doses have been administered globally, but over 81% have gone to high- or upper middle-income countries, while low-income countries have received just 0.3%,” WHO director-general Tedros Adhanom Ghebreyesus said.“Nearly 900 million vaccine doses have been administered globally, but over 81% have gone to high- or upper middle-income countries, while low-income countries have received just 0.3%,” WHO director-general Tedros Adhanom Ghebreyesus said.
The agreement follows recent findings by the EMA that two other vaccines – AstraZeneca’s and Johnson & Johnson’s – may be linked to very rare but potentially deadly cases of blood clotting in some people. Both vaccines are based on viral vector technology, while that of Pfizer/BioNTech uses messenger RNA (mRNA) technology.The agreement follows recent findings by the EMA that two other vaccines – AstraZeneca’s and Johnson & Johnson’s – may be linked to very rare but potentially deadly cases of blood clotting in some people. Both vaccines are based on viral vector technology, while that of Pfizer/BioNTech uses messenger RNA (mRNA) technology.
The European Commission is also looking to stop cooperation with AstraZeneca after the British-Swedish company slashed its delivery targets due to production problems.The European Commission is also looking to stop cooperation with AstraZeneca after the British-Swedish company slashed its delivery targets due to production problems.
Like this story? Share it with a friend!Like this story? Share it with a friend!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.